Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of VCN Biosciences.

    Client Virtual Booth

    VCN BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    VCN Biosciences
    Spain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Av. de la Generalitat, 152 08174, Sant Cugat del Vallès, BCN
    Telephone
    Telephone
    +34 93 571 23 59
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.vcnbiosciences.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

    Details:

    VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.


    Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

    Therapeutic Area: Oncology Product Name: VCN-01

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Theriva Biologics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 22, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Synthetic Biologics Completes Acquisition of VCN Biosciences

    Details:

    The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with high unmet need.


    Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

    Therapeutic Area: Oncology Product Name: VCN-01

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Theriva Biologics

    Deal Size: $4.7 million Upfront Cash: Undisclosed

    Deal Type: Acquisition March 11, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Synthetic Biologics Announces VCN Biosciences’ VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

    Details:

    VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.


    Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

    Therapeutic Area: Oncology Product Name: VCN-01

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Theriva Biologics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 08, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic ...

    Details:

    VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending.


    Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

    Therapeutic Area: Oncology Product Name: VCN-01

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Grifols International

    Deal Size: $77.4 million Upfront Cash: $4.7 million

    Deal Type: Acquisition December 14, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search